PRPO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PR

Mkt Cap

$38.5M

Volume

94.23K

Next Earnings

November 13th

Loading chart

PR

PRPOPrecipio, Inc. Common Stock

PRPO

Pay with—

Available Balance0.00

PR

Mkt Cap

$40.4M

Volume

94.23K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?Both Precipio and Fulgent Genetics operate in specialty diagnostics with exposure to oncology, but Fulgent Genetics is recommended as the better investment choice. FLGT offers a more diversified growth platform through recent acquisitions (Bako Diagnostics, StrataDx), AI/digital pathology investments, and a therapeutic pipeline, while trading below its historical valuation median. PRPO shows improving fundamentals and cash generation but trades above its five-year median, suggesting its progress is already priced in.Zacks Investment Research · Sep 22, 2026

Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders MeetingPrecipio Inc. (NASDAQ: PRPO) is urging shareholders to vote immediately to reach the 50% quorum requirement for its Annual Shareholders Meeting scheduled for June 15, 2026. As of the press release date, only 42% of shares had been voted. The company is seeking to avoid costly adjournment and rescheduling expenses if sufficient votes are not received by the June 14 deadline.GlobeNewswire Inc. · Jun 12, 2026

Precipio to Present at the Planet MicroCap Las VegasPrecipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, announced it will present at the Planet MicroCap Las Vegas 2026 conference on June 17, 2026. CEO Ilan Danieli and COO Zaki Sabet will host the presentation. The company emphasized it is profitable and focused on raising awareness and building its shareholder base rather than raising capital.GlobeNewswire Inc. · Jun 11, 2026

Precipio Announces Q1 2026 Financial ResultsPrecipio, Inc. (NASDAQ: PRPO) reported Q1-2026 revenue of $6.71M, essentially flat compared to Q4-2025, driven by timing dynamics including delayed product shipments and CMS cuts. Adjusted EBITDA declined to $(0.16)M from $0.96M in Q4-2025, impacted by lower gross profits, new hiring costs, and bonus payments. Management attributes the flat performance to temporary factors and expects second-half growth from an expanding product pipeline developed by the newly hired commercial team.GlobeNewswire Inc. · May 14, 2026

Management team’s 2025 market-based Options have vestedPrecipio, Inc. (NASDAQ: PRPO) announced that 2025 employee stock options for management vested after the company's stock price increased 400% to a 10-day VWAP of $30.30 from the grant price of $6.06. The company replaced traditional time-based vesting with market-based vesting to align management incentives with shareholder interests. A similar structure was implemented for 2026 options with a target price of $40, resulting in an $800,000 non-cash stock compensation expense in Q1 2026.GlobeNewswire Inc. · May 13, 2026

Precipio Announces Q1-2026 Shareholder Update CallPrecipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, announced it will host its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET. The call will feature management remarks on core businesses and will mark the first time the company incorporates a dedicated moderated live Q&A session into its quarterly update call, demonstrating the company's commitment to shareholder transparency and engagement.GlobeNewswire Inc. · May 6, 2026

Precipio Announces Q4 and year-end 2025 Shareholder Update CallPrecipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, announced a corporate update call scheduled for April 2, 2026, to discuss Q4 and year-end 2025 results. The company reported preliminary unaudited revenues of $24.0M for 2025, representing a 30% year-over-year increase. Additionally, Precipio published a joint study with Memorial Sloan-Kettering Cancer Center on its Bloodhound BCR::ABL1 assay in the Journal of Clinical Pathology.GlobeNewswire Inc. · Mar 12, 2026

Precipio Takes Major Steps Toward a Clean Balance SheetSpecialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced significant balance sheet improvements by repaying a $1.1 million advance from Change Healthcare and completing the exercise of all financial warrants issued in 2023. The company now maintains a nearly debt-free balance sheet with only an $80,000 Connecticut state loan remaining, positioning itself to focus on profitable operations and shareholder value creation.GlobeNewswire Inc. · Jan 15, 2026

Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) MeetingPrecipio conducted a comprehensive study with Memorial Sloan Kettering Cancer Center, evaluating their BCR::ABL1 assay using 895 patient samples. The study demonstrated superior performance and positive impacts on patient care and laboratory workflows.GlobeNewswire Inc. · Dec 5, 2025

Precipio Announces Q3-2025 Shareholder Update CallSpecialty cancer diagnostics company Precipio will host its Q3-2025 corporate update call on November 17th, 2025 at 5:00 PM ET, providing updates on its core businesses and diagnostic technologies.GlobeNewswire Inc. · Nov 4, 2025

to start trading

PR

PRPOPrecipio, Inc. Common Stock

PRPO

Pay with—

Available Balance0.00

Your PositionYou don't own any PRPO yet.

Related Tickers

Earnings